Conference Coverage (12th World AIDS)
SF Health Department Defends Controversial Plan
Published in Blood Weekly, July 27th, 1998
San Francisco health authorities say they will forge ahead with a controversial study that provides antiretroviral drugs to people who think they may have been exposed to HIV.
The trial program, known as post-exposure prophylaxis (PEP), is aimed at people who have had unsafe sex or needle-sharing with an HIV infected partner. Although the program provides anti-HIV drugs, it is intended as a risk reduction program and not as a medical intervention.
"If we get people in who are very scared after a high-risk exposure, this is a very good opportunity for counseling interventions,"...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (1998-07-27)
More Articles from Blood Weekly
- GB Virus C
High Prevalence of GBV-C in Volunteer Blood Donors in South Africa - Animal Models
Targeted Gene Inactivation Results in Murine Hemophilia B Model - Animal Models (HSV)
ICP47 Blocks TAP and MHC Antigen Presentation in Animals - Bone Marrow Transplantation
Functional Subset of Donor CD8 Cells Inhibits Graft Rejection - Bone Marrow Transplantation
GVHD and Prevention of Rejection May Be Separable Effects - Cytomegalovirus
Viral Mutant Resistant to Fomivirsen Derivative Is Isolated - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
